Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T
200 Jobs Shed And Pipeline Cut Back
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.
You may also be interested in...
Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.
Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.
Having established Enhertu as their first antibody-drug conjugate blockbuster, AstraZeneca and Daiichi Sankyo are looking to challenge Gilead in the TROP2-targeting field as well.